KIT and gastrointestinal stromal tumor: Imatinib, which binds directly to the KIT receptor, was shown to have no appreciable effect on the KIT promoter.36 BRD4 inhibition resulting from combined therapy minimized KIT dependency and improved the sensitivity to imatinib in resistant GIST cells in vitro and in vivo.